DA3531 CD309 / VEGFR-2 / Flk-1 (D1-7) (Fc Chimera)

Search for all "CD309 / VEGFR-2 / Flk-1"

50 µg / €280.00
Delivery Time: 3-5 working days

Quick Overview

CD309 / VEGFR-2 / Flk-1

DA3531

Product Description for CD309 / VEGFR-2 / Flk-1

CD309 / VEGFR-2 / Flk-1.
Presentation: Purified

Properties for CD309 / VEGFR-2 / Flk-1

Product Category Proteins
Quantity 50 µg
Synonyms FLK1, FocusOn005, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2
Presentation Purified
Molecular weight 160 kDa
Source Insect cells
Species (Protein) Human
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer Acris Antibodies GmbH

Datasheet Extract

Immunogen
Swiss Prot Num:
P35968
Purity > 90 %
Add. information Centrifuge vials before opening!
Background Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin.
General Readings
  • Röckl et al., Exp Cell Res 241:161, 1998.
Storage Store Lyophilized at -20°C to -70°C.
Reconstituted sVEGFR-2/Fc should be stored in working aliquots at -20°C.
Avoid repeated freeze-thaw cycles!
Shelf life: One year from despatch.
Description
Biological activity:
The activity of sVEGFR-2/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of Human umbilical vein endothelial cells.
The ED50 for this effect is typically 10-30 ng/ml.
Format
Buffer System:
PBS, pH 7.2 without stabilizers.
Endotoxin level:
< 0.1 ng per µg of sVEGFR-2.
Purity:
by SDS-PAGE and visualised by silver stain.
State:
Lyophilized purified protein
Purified
Reconstitution:
Restore in PBS or medium to a concentration not lower than 50 µg/ml.
The lyophilised sVEGFR-2/Fc is soluble in water and most aqueous buffers.
Targets